Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Medicina (Kaunas). 2024 Oct 31;60(11):1783. doi: 10.3390/medicina60111783.
: Alzheimer's disease and other dementias represent some of the leading public health concerns worldwide. This study aimed to assess the global burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose in the last decades. : A descriptive epidemiological study was conducted. The Global Burden of Disease (GBD) study data about deaths and Disability-Adjusted Life Years (DALYs) were used. All figures were presented as age-standardized rates (ASRs). The average annual percent change (AAPC) was computed using the Joinpoint regression analysis. Also, age-period-cohort analysis was performed. : A total of 2 million deaths from Alzheimer's disease and other dementias were reported worldwide in 2021, whereby the total number deaths from Alzheimer's disease and other dementias attributable to high fasting plasma glucose was 290,032 (98,900 males and 191,132 females) in 2021. The highest ASRs of burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose were found in Afghanistan, Iraq, Morocco, Qatar, and the United States of America, while the lowest ASRs were in Belarus and Mongolia. From 1990 to 2021, a significant increase ( < 0.001) was noted in ASRs of deaths and DALYs for Alzheimer's disease and other dementias attributable to high fasting plasma glucose. Looking at the GBD regions, the trends in ASRs for mortality and for DALYs of Alzheimer's disease and other dementias attributable to high fasting plasma glucose between 1990 and 2021 showed a growth 10-fold faster in High-income North America (AAPC = 2.0%, for both equally) and Central Asia (AAPC = 2.4% and AAPC = 2.5%, respectively) than in the region of High-income Asia Pacific (AAPC = 0.1% and AAPC = 0.2%, respectively). The relative risk of mortality and DALYs for Alzheimer's disease and other dementias attributable to high fasting plasma glucose demonstrated statistically significant ( < 0.0001) period and cohort effects, and net drift and local drifts. : This study showed an increase in the global burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose in the last decades. Future successful entire-population strategies targeting high fasting plasma glucose may reduce the burden of a wide range of these diseases.
: 阿尔茨海默病和其他痴呆症是全球主要的公共卫生问题之一。本研究旨在评估过去几十年中因高空腹血糖导致的阿尔茨海默病和其他痴呆症的全球负担。: 进行了一项描述性流行病学研究。使用了全球疾病负担(GBD)研究关于死亡和伤残调整生命年(DALY)的数据。所有数据均以年龄标准化率(ASR)表示。使用 Joinpoint 回归分析计算平均年百分比变化(AAPC)。还进行了年龄-时期-队列分析。: 2021 年,全球有 200 万人死于阿尔茨海默病和其他痴呆症,其中因高空腹血糖导致的阿尔茨海默病和其他痴呆症死亡人数为 290032 人(男性 98900 人,女性 191132 人)。2021 年,因高空腹血糖导致的阿尔茨海默病和其他痴呆症负担的最高 ASR 见于阿富汗、伊拉克、摩洛哥、卡塔尔和美利坚合众国,而最低 ASR 见于白俄罗斯和蒙古。1990 年至 2021 年,因高空腹血糖导致的阿尔茨海默病和其他痴呆症死亡和 DALY 的 ASR 显著增加(<0.001)。从 GBD 区域来看,1990 年至 2021 年,高收入北美(死亡率和 DALY 的 ASR 分别为 2.0%)和中亚(死亡率和 DALY 的 ASR 分别为 2.4%和 2.5%)的高收入地区因高空腹血糖导致的阿尔茨海默病和其他痴呆症的死亡率和 DALY 趋势呈 10 倍增长,而高收入亚太地区(死亡率和 DALY 的 ASR 分别为 0.1%和 0.2%)。因高空腹血糖导致的阿尔茨海默病和其他痴呆症的死亡率和 DALY 的相对风险显示出具有统计学意义的(<0.0001)时期和队列效应,以及净漂移和局部漂移。: 本研究表明,过去几十年中因高空腹血糖导致的阿尔茨海默病和其他痴呆症的全球负担有所增加。未来针对高空腹血糖的全人群成功策略可能会降低多种此类疾病的负担。